Jiangsu Hengrui Pharmaceuticals Co., Ltd.SSE: 600276

Announcement on Progress in A-share Repurchase

Jun 3, 2026 · Issued by Jiangsu Hengrui Pharmaceuticals Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Jun 3, 2026

On 6ix: 6ix.com/news/announcement-on-progress-in-a-share-repurchase

Announcement on Progress in A-share Repurchase

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. on 6ix

Earlier from Jiangsu Hengrui Pharmaceuticals

Announcement on Convening the Q1 2026 Performance BriefingMay 28
Announcement on Implementation of Dividend Distribution for 2025May 21
Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and ImmunologyMay 12
Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Non-Obstructive Hypertrophic CardiomyopathyMay 11
Announcement on Resolutions of the 3rd Meeting of the 10th Board of DirectorsApr 30

Later from Jiangsu Hengrui Pharmaceuticals

Announcement on Obtaining Notice of Approval for Drug Clinical TrialJun 17
Indicative Announcement on Acceptance of Application for Drug Marketing Authorization by EMAJun 23
Announcement on Withdrawal of Drug Registration ApplicationJun 24
Announcement on Obtaining Drug Registration ApprovalJun 26
Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye DiseaseJun 30

All Jiangsu Hengrui Pharmaceuticals news releases

Follow Jiangsu Hengrui Pharmaceuticals into a list and get an email when it puts out news.

Follow Jiangsu Hengrui Pharmaceuticals